PMID- 38422562
OWN - NLM
STAT- MEDLINE
DCOM- 20240401
LR  - 20240508
IS  - 1873-460X (Electronic)
IS  - 1056-8727 (Linking)
VI  - 38
IP  - 4
DP  - 2024 Apr
TI  - Increased skeletal muscle mass index was involved in glycemic efficacy following 
      diabetes treatment, and changes in fat mass index correlated with the changes in 
      the lipid ratio in type 2 diabetes.
PG  - 108717
LID - S1056-8727(24)00043-6 [pii]
LID - 10.1016/j.jdiacomp.2024.108717 [doi]
AB  - AIM: This study aimed to investigate the association between changes in body 
      composition, glycated hemoglobin, and lipid ratio during the treatment of 
      patients with type 2 diabetes mellitus (T2DM). METHODS: This retrospective 
      analysis used data from outpatients with T2DM who had confirmed body composition 
      and measured laboratories at administration and after treatment. The baseline 
      characteristics and prescribed treatment were collected. The total 
      cholesterol/high-density lipoprotein cholesterol (HDL) ratio, low-density 
      lipoprotein cholesterol (LDL)/HDL ratio, and triglyceride-glucose (TyG) index 
      were also calculated. RESULTS: A total of 207 patients (mean patient age, 
      62.0 +/- 13.7 years; 68.1 % males) were enrolled. Fat mass index (FMI) changes 
      correlated with the changes in the lipid ratio, whereas skeletal muscle mass 
      index (SMI) changes inversely correlated with glycated hemoglobin (HbA1c) 
      changes. Multiple regression analysis showed that changes in LDL/HDL and TyG 
      correlated with FMI changes (t = 2.388, p = 0.017, t = 2.022, p = 0.044). 
      Conversely, HbA1c changes correlated with SMI changes (t = -2.552, p = 0.011). 
      CONCLUSION: In patients with T2DM, increased SMI was involved in glycemic 
      efficacy, and FMI changes were associated with LDL/HDL and TyG.
CI  - Copyright (c) 2024 Elsevier Inc. All rights reserved.
FAU - Matsuura, Shun
AU  - Matsuura S
AD  - Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 
      4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan; Division of Respiratory 
      Internal Medicine, Fujieda Municipal General Hospital, 4-1-11, Surugadai, 
      Fujieda, Shizuoka 426-8677, Japan. Electronic address: s_shun_shun@yahoo.co.jp.
FAU - Nagata, Soichiro
AU  - Nagata S
AD  - Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 
      4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan.
FAU - Shibazaki, Koji
AU  - Shibazaki K
AD  - Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 
      4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan.
FAU - Uchida, Reiko
AU  - Uchida R
AD  - Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 
      4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan.
FAU - Imai, Yukiko
AU  - Imai Y
AD  - Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 
      4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan.
FAU - Shibata, Shoko
AU  - Shibata S
AD  - Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 
      4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan.
FAU - Morita, Hiroshi
AU  - Morita H
AD  - Division of Diabetes Endocrinology Medicine, Fujieda Municipal General Hospital, 
      4-1-11, Surugadai, Fujieda, Shizuoka 426-8677, Japan.
LA  - eng
PT  - Journal Article
DEP - 20240227
PL  - United States
TA  - J Diabetes Complications
JT  - Journal of diabetes and its complications
JID - 9204583
RN  - 0 (Glycated Hemoglobin)
RN  - 0 (Blood Glucose)
RN  - 0 (Triglycerides)
RN  - 0 (Cholesterol, LDL)
RN  - 0 (Cholesterol, HDL)
RN  - IY9XDZ35W2 (Glucose)
SB  - IM
MH  - Male
MH  - Humans
MH  - Middle Aged
MH  - Aged
MH  - Female
MH  - *Diabetes Mellitus, Type 2/complications/drug therapy
MH  - Glycated Hemoglobin
MH  - Blood Glucose
MH  - Retrospective Studies
MH  - Triglycerides
MH  - Cholesterol, LDL
MH  - Cholesterol, HDL
MH  - Glucose
MH  - Muscle, Skeletal
OTO - NOTNLM
OT  - Body composition
OT  - Cholesterol high-density lipoprotein
OT  - DPP-4 inhibitors
OT  - HbA1c
OT  - Low-density lipoprotein cholesterol
OT  - Type 2 diabetic mellitus
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2024/02/29 18:42
MHDA- 2024/04/01 06:42
CRDT- 2024/02/29 18:00
PHST- 2023/08/31 00:00 [received]
PHST- 2023/11/01 00:00 [revised]
PHST- 2024/02/26 00:00 [accepted]
PHST- 2024/04/01 06:42 [medline]
PHST- 2024/02/29 18:42 [pubmed]
PHST- 2024/02/29 18:00 [entrez]
AID - S1056-8727(24)00043-6 [pii]
AID - 10.1016/j.jdiacomp.2024.108717 [doi]
PST - ppublish
SO  - J Diabetes Complications. 2024 Apr;38(4):108717. doi: 
      10.1016/j.jdiacomp.2024.108717. Epub 2024 Feb 27.